<name>Guardian Bio</name> <description>Guardian Bio advances cell‑based immunotherapies by applying dendritic‑cell platforms and marine‑derived compounds to develop personalized treatments for cancer and infectious diseases. The company combines contract manufacturing expertise with academic research to accelerate
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer patients often experience dendritic cell dysfunction, which impairs the immune system's ability to recognize and attack tumor cells. Traditional cancer treatments can further suppress immune function, limiting their long-term effectiveness.
Solution
Guardian Bio engineers personalized cell therapies using patient-derived stem cells to generate functional, cancer-targeted dendritic cells. These engineered dendritic cells are designed to stimulate a robust anti-tumor immune response, overcoming the immune suppression often seen in cancer patients. By revitalizing the immune system, Guardian Bio's approach aims to enhance the body's natural ability to fight cancer. The personalized nature of the therapy ensures that the dendritic cells are specifically tailored to recognize and target the unique characteristics of each patient's cancer.
Target Audience
Guardian Bio's primary target audience includes cancer patients with solid tumors or hematological malignancies who have failed to respond to standard therapies, as well as oncologists seeking innovative treatment options for their patients.
Features
- Patient-specific dendritic cells derived from induced pluripotent stem cells (iPSCs).
- Cancer-specific antigen loading to direct immune response towards tumor cells.
- Proprietary differentiation protocols to generate highly functional dendritic cells.
- Enhanced T-cell activation and proliferation for improved anti-tumor immunity.
- GMP-grade manufacturing process to ensure product safety and consistency.